TSE:4587Biotechs
PeptiDream (TSE:4587) Q1 Loss Of ¥854m Tests Bullish Profitability Narratives
PeptiDream (TSE:4587) opened Q1 2026 with revenue of ¥4,764 million and a basic EPS loss of ¥6.61, alongside a net loss of ¥854 million, setting a cautious tone for the latest update. Over recent quarters the company reported revenue of ¥4,233 million in Q1 2025 and ¥5,663.62 million in Q4 2025 before landing at ¥4,764 million this quarter. Quarterly EPS losses have ranged from ¥4.11 to ¥8.47 across that period, so the market is likely to focus on how much of the current revenue base is...